

FIRST TIME GENERIC APPROVAL

Brand Name	Noxafil® Oral Suspension
Generic Name	posaconazole oral suspension
Drug Manufacturer	Hikma Pharmaceuticals USA, Inc

New Drug Approval

Dosage form(s): 200 mg/5 mL (40 mg/mL) Oral Suspension

Therapeutic equivalent code: AB

FDA Approval Date: May 15, 2020

Indications for Use

posaconazole oral suspension is indicated for:

- For the prophylaxis of invasive *Aspergillus* and *Candida* infections in patients who are at high risk of developing these infections due to being severely immunocompromised, and for the treatment of oropharyngeal candidiasis

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.